PMID- 30489484
OWN - NLM
STAT- MEDLINE
DCOM- 20190614
LR  - 20190614
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 29
IP  - 2
DP  - 2019 Apr
TI  - Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and 
      a literature review.
PG  - 212-215
LID - 10.1097/CMR.0000000000000536 [doi]
AB  - Nivolumab is widely used to treat several late-stage malignancies such as 
      melanoma and non-small-cell lung cancer by inhibiting the interaction between the 
      programmed cell death protein-1 and its ligand. By stimulating an antitumor 
      immune response, it also leads to immune adverse events. Here. we report two 
      cases of subacute cutaneous lupus erythematosus (SCLE) induced by nivolumab. Case 
      1: a 72-year-old woman with a stage IV melanoma. Two months after nivolumab 
      discontinuation because of autoimmune hepatitis, the patient was in complete 
      remission and pruritic nummular erythematous plaques appeared on the back and 
      arms. Case 2: a 43-year-old man put under nivolumab for a metastatic 
      non-small-cell lung cancer. After two cycles, an annular erythematous eruption 
      appeared on the hands, arms, and chest. The hypothesis of SCLE was confirmed by 
      biopsies showing lymphoid perivascular inflammatory infiltrates, with scarce C3 
      deposits along the basal layer of the epidermis in patient 2. Both patients 
      tested positive for antinuclear antibodies and anti-SSA antibodies. Lesions were 
      regressive under topical corticosteroids and hydroxychloroquine for the first 
      patient and oral prednisone for the second patient. No systemic involvement was 
      observed. The occurrence of SCLE 2 months after nivolumab discontinuation is 
      evidence that the drug effect is prolonged because of the maintenance of 
      programmed cell death protein-1 reception saturation for months. A causal 
      relationship between SCLE and nivolumab is suggested by (i) the occurrence of 
      SCLE after at least two cycles, (ii) the regression of lesions following 
      treatment with corticosteroids and hydroxychloroquine, and (iii) the fact that it 
      appeared after remission in our first patient.
FAU - Zitouni, Nesrine B
AU  - Zitouni NB
AD  - Departments of Dermatology.
FAU - Arnault, Jean-Philippe
AU  - Arnault JP
AD  - Departments of Dermatology.
FAU - Dadban, Ali
AU  - Dadban A
AD  - Departments of Dermatology.
FAU - Attencourt, Christophe
AU  - Attencourt C
AD  - Pathology, Amiens University Hospital, Amiens, France.
FAU - Lok, Catherine C
AU  - Lok CC
AD  - Departments of Dermatology.
FAU - Chaby, Guillaume
AU  - Chaby G
AD  - Departments of Dermatology.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/pathology
MH  - Male
MH  - Nivolumab/*adverse effects/pharmacology
EDAT- 2018/11/30 06:00
MHDA- 2019/06/15 06:00
CRDT- 2018/11/30 06:00
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/06/15 06:00 [medline]
PHST- 2018/11/30 06:00 [entrez]
AID - 10.1097/CMR.0000000000000536 [doi]
PST - ppublish
SO  - Melanoma Res. 2019 Apr;29(2):212-215. doi: 10.1097/CMR.0000000000000536.